474 related articles for article (PubMed ID: 32538234)
1. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges.
Chen A; Stecker E; A Warden B
J Am Heart Assoc; 2020 Jul; 9(13):e017559. PubMed ID: 32538234
[TBL] [Abstract][Full Text] [Related]
2. Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs).
Hussain SS; Tyroch AH; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):76-81. PubMed ID: 27215215
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.
Shaw J; de Wit C; Le Gal G; Carrier M
J Thromb Haemost; 2017 May; 15(5):925-930. PubMed ID: 28296069
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
[TBL] [Abstract][Full Text] [Related]
5. A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant.
Wadsworth D; Sullivan E; Jacky T; Sprague T; Feinman H; Kim J
J Clin Pharm Ther; 2021 Jun; 46(3):560-570. PubMed ID: 33393699
[TBL] [Abstract][Full Text] [Related]
6. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians.
Douxfils J; Ageno W; Samama CM; Lessire S; Ten Cate H; Verhamme P; Dogné JM; Mullier F
J Thromb Haemost; 2018 Feb; 16(2):209-219. PubMed ID: 29193737
[TBL] [Abstract][Full Text] [Related]
7. Use of direct oral anticoagulants in antiphospholipid syndrome.
Cohen H; Efthymiou M; Isenberg DA
J Thromb Haemost; 2018 Jun; 16(6):1028-1039. PubMed ID: 29624847
[TBL] [Abstract][Full Text] [Related]
8. Direct Oral Anticoagulants: Navigating Through Clinical Challenges.
Ioannou M; Leonidou E; Chaziri I; Mouzarou A
Cardiovasc Drugs Ther; 2024 Jun; 38(3):637-650. PubMed ID: 37552381
[TBL] [Abstract][Full Text] [Related]
9. Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants.
Ten Cate H; Henskens YM; Lancé MD
Vasc Health Risk Manag; 2017; 13():457-467. PubMed ID: 29263674
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants.
Bavalia R; Middeldorp S; Weisser G; Espinola-Klein C
Thromb Haemost; 2020 Jun; 120(6):899-911. PubMed ID: 32492723
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulation at the extremes of body weight: choices and dosing.
McCaughan GJB; Favaloro EJ; Pasalic L; Curnow J
Expert Rev Hematol; 2018 Oct; 11(10):817-828. PubMed ID: 30148651
[TBL] [Abstract][Full Text] [Related]
12. Unresolved issues in the use of direct acting oral anticoagulants.
Chan N; Hirsh J
Expert Rev Cardiovasc Ther; 2023; 21(12):913-921. PubMed ID: 37837206
[TBL] [Abstract][Full Text] [Related]
13. Bleeding and thrombotic outcomes associated with postoperative use of direct oral anticoagulants after open peripheral artery bypass procedures.
Obi AT; Thompson JR; Beaulieu RJ; Sutzko DC; Osborne N; Albright J; Gallagher KA; Henke PK
J Vasc Surg; 2020 Dec; 72(6):1996-2005.e4. PubMed ID: 32278573
[TBL] [Abstract][Full Text] [Related]
14. Quick reference guide to apixaban.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2017; 13():263-267. PubMed ID: 28744136
[TBL] [Abstract][Full Text] [Related]
15. Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics.
Mohammad I; Korkis B; Garwood CL
Pharmacotherapy; 2017 Oct; 37(10):1284-1297. PubMed ID: 28730690
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes.
Davis KA; Joseph J; Nisly SA
J Thromb Thrombolysis; 2020 Aug; 50(2):457-461. PubMed ID: 31915998
[TBL] [Abstract][Full Text] [Related]
17. Assessing patient preferences for switching from warfarin to direct oral anticoagulants.
Wright JN; Vazquez SR; Kim K; Jones AE; Witt DM
J Thromb Thrombolysis; 2019 Nov; 48(4):596-602. PubMed ID: 31273515
[TBL] [Abstract][Full Text] [Related]
18. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
[TBL] [Abstract][Full Text] [Related]
19. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
20. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
Desai NR; Cornutt D
Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
